摘要
肺动脉高压（PAH）是由肺动脉渐进性闭塞导致肺血管阻力（PVR）逐渐升高进而发生右心室衰竭的一种耗竭性疾病。PAH的病理生理学特征为由血管重构、血管收缩和细胞增生所致的进行性PVR升高。随着对PAH病理生理学认识的逐渐深入,
出处
《临床荟萃》
CAS
2013年第6期703-706,共4页
Clinical Focus
参考文献20
-
1Agarwal R, Gomberg-Maitland M. Current therapeutics and practical management strategies for pulmonary arterial hypertension[J]. Am Heart J,2011,162(2):201-213.
-
2Nef HM, Mollmann H, Hamm C, et al. Pulmonary hypertension: updated classification and management of pulmonary hypertension[J]. Heart, 2010,96 (7) 552-559.
-
3Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension [J]. Eur Heart J,2009,30(4)..394-403.
-
4Doran A, Ivy D, Barst R, et al. Guidelines for the prevention of central venous catheter - related blood stream infections with prostanoid therapy for pulmonary arterial hypertension[J]. Int J Clin Pract Suppl,2008,(160) :5-9.
-
5MeLaughlin VV,Benza RL,Rubin LJ,et al. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension:a randomized controlled ctinical trial[J]. J Am Coll Cardiol,2010,55(18) : 1915-1922.
-
6Gomberg-Maitland M, Olschewski H. Prostacyclin therapies for the treatment of pulmonary arterial hypertension[J]. Eur Respir J,2008,31(4) :891-901.
-
7Lourenco AP,Fontoura D, Henriques-Coelho T, et al. Current pathophysiological concepts and management of pulmonary hypertension[J]. Int J Cardiol, 2012,155 (3): 350-361.
-
8Rhodes CJ,Davidson A,Gibbs JS,et aI. Therapeutic targets in pulmonary arterial hypertension[J]. Pharmaeol Ther, 2009, 121(1):69-88.
-
9Galle N,Rubin L,Hoeper M,et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan ( EARLY study ) : a double-blind, randomized controlled trial[J]. Lancet, 2008,371 (9630) : 2093-2100.
-
10Jais X,d'Armini AM,Jansa P,et al. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFIT (Bosentan Effects in iNopErable Forms of chronic Thromboembolic pulmonary hypertension ), a randomized, placebo-controlled trial[J]. J Am Coll Cardiol, 2008,52 (25) : 2127-2134.
同被引文献50
-
1申国璋,沈向前.先天性心脏病合并肺动脉高压治疗的研究进展[J].心血管病学进展,2006,27(4):495-498. 被引量：16
-
2张海燕,郭艺芳.肺动脉高压的药物治疗进展[J].河北医科大学学报,2007,28(3):228-231. 被引量：2
-
3无.肺动脉高压筛查诊断与治疗专家共识[J].中华心血管病杂志,2007,35(11):979-987. 被引量：281
-
4Galie N, Manes A, Palazzini M, et al. Management of pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger "s syn- drome [ J ]. Drugs, 2008,68 ( 8 ) : 1049-1066.
-
5Chemla D, Castelain V, Herve P, et al. Haemodynamic evaluation of pulmonary hypertension [ J ]. Eur Respir J, 2002,20(5) :1314-1331.
-
6DAlonzo G E, Barst R J, Ayres S M, et al. Survival inpatients with primary pulmonary hypertension. Results from a national prospective registry[ J]. Ann Intern Med, 1991,115(5) :343-349.
-
7Galie N, Hoeper M M, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertSnsion: the Task Force for the Diagnosis and Treatment of Pulmo- nary Hypertension of the European Society of Cardiology ( ESC ) and the European Respiratory Society (ERS) , endorsed by the International Society of Heart and Lung Transplantation (ISHLT) [ J ]. Eur Heart J, 2009, 30 (20) :2493-2537.
-
8Frampton James E. Ambrisentan [ J]. Am J Cardiovasc Drugs, 2011,11 (4) :215-226.
-
9Galie N, Olschewski H, Oudiz R J, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: re- suits of the ambrisentan in pulmonary arterial hyperten- sion, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2[ J]. Circu- lation, 2008,117 ( 23 ) : 3010-3019.
-
10Barst Robyn J. A review of pulmonary arterial hyperten- sion: role of ambrisentan [ J ]. Vasc Health Risk Manag, 2007,3 ( 1 ) : 11-22.
引证文献4
-
1刘洋,张刚成,周红梅,尚小珂.安立生坦治疗肺动脉高压42例临床观察[J].解放军医药杂志,2014,26(6):8-11. 被引量：1
-
2高磊,刘昕,张静波,耿戟,庞真贞.肺动脉高压患者超声心动图常规参数与右心导管测值相关性研究[J].河北医科大学学报,2015,36(5):547-550. 被引量：10
-
3全峰,范雪梅,方文龙.系统性红斑狼疮患者合并肺动脉高压的临床特点[J].临床荟萃,2015,30(12):1402-1405. 被引量：3
-
4程国栋,曹勇,朱春磊,李小芳.曲前列尼尔在先天性心脏病合并重度肺动脉高压围术期的应用[J].岭南急诊医学杂志,2019,0(4):330-332. 被引量：1
二级引证文献15
-
1于韶光.让我们做个视频玩家：——开栏的话[J].高保真音响,2000(3):30-31.
-
2谭如娅.糖皮质激素与环磷酰胺联合西地那非治疗系统性红斑狼疮合并肺动脉高压的效果分析[J].中国药物经济学,2018,13(12):56-58. 被引量：5
-
3黄杰,曾春来,吕玲春.波生坦片治疗慢性阻塞性肺疾病肺动脉高压效果分析[J].中国现代医生,2016,54(29):39-42. 被引量：4
-
4赵万桂,顾虹.超声心动图评估肺动脉高压的研究进展[J].心肺血管病杂志,2016,35(12):1005-1007. 被引量：9
-
5蓝仁洁,丁雪,蒙正猛.超声心动图评价肺动脉高压患者右心功能的价值分析[J].内科,2017,12(2):263-264. 被引量：2
-
6杜梅素,李朝鹏,王亮亮,李娜,杜景霞.间尼索地平对低氧性肺动脉高压大鼠的作用[J].河北医科大学学报,2018,39(1):11-14. 被引量：1
-
7吴扬燕,崔跃,梁敏群,利建.心脏彩色多普勒超声对肺动脉高压的诊断价值[J].深圳中西医结合杂志,2018,28(1):44-46. 被引量：1
-
8王传玉,吴文汇,郭健,姜蓉,宫素岗,赵勤华,孙行行,杨怡兰,王岚,刘锦铭.常规肺功能检查对COPD相关性肺动脉高压的筛查和评估价值[J].国际呼吸杂志,2019,39(4):281-288. 被引量：9
-
9邓晓娴,夏成,周红梅.安立生坦对异丙肾上腺素诱导大鼠心肌纤维化保护作用及机制研究[J].解放军预防医学杂志,2020,38(2):47-50. 被引量：3
-
10赵谊昶(综述),陈菲菲(审校).肺动脉高压评估与诊断方法研究进展[J].海南医学,2020,31(12):1596-1600. 被引量：3
-
1梁旭竞.慢性乙型肝炎抗病毒治疗的进展[J].临床荟萃,2005,20(6):352-354. 被引量：9
-
2王凌玲,雷梦觉,涂燕平,邬甦.氟伐他汀对慢性阻塞性肺疾病患者合并肺动脉高压的治疗作用[J].中国老年学杂志,2011,31(9):1666-1667. 被引量：24
-
3王凯玲,任涛.肺动脉高压药物治疗的新进展[J].国际呼吸杂志,2015,35(10):796-800. 被引量：1
-
4徐飞,董竞成.哮喘-慢性阻塞性肺疾病重叠综合征的临床研究进展[J].中国全科医学,2016,19(5):500-506. 被引量：49
-
5张雷,Gregg Hadley.CD103分子介导CD8^＋T淋巴细胞对同种胰岛移植物的损伤[J].中华器官移植杂志,2011,32(2):91-94. 被引量：2
-
6季旻晔,张凤如.右心室功能不全的研究热点及难点[J].临床心血管病杂志,2009,25(4):244-247. 被引量：2
-
7陈建新.ST_Ⅲ↑/ST_Ⅱ↑>1诊断下壁合并右室心肌梗死的临床价值[J].实用心电学杂志,2008,17(3):163-164. 被引量：7
-
8赵永成.老年性高血压病的特点及治疗[J].医学信息,2013(2):288-288.
-
9吴晓东.老年人高血压的特点及治疗[J].医学信息（下旬刊）,2009(7):263-264.
-
10王秋芬,廖玉华.欧洲心脏病协会2004年肺动脉高压诊断和治疗指南简介[J].临床心血管病杂志,2005,21(7):385-386. 被引量：58
